TRIB (Trinity Biotech) EPS (Basic): $-2.00 (TTM As of Dec. 2025)


TRIB Trinity Biotech PLC TRIB
20 GF Score
Price $0.33
GF Value $0.73
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Trinity Biotech EPS (Basic)?

Trinity Biotech TRIB -5.69% 20 EPS (Basic) is $-2.00 as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 20/100 and a GF Value™ of $0.73 (Possible Value Trap). The stock has 7 warning signs investors should review.

Trinity Biotech's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was $-1.20. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.00.

Trinity Biotech's EPS (Diluted) for the six months ended in Dec. 2025 was $-1.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.00.

Trinity Biotech's EPS without NRI for the six months ended in Dec. 2025 was $-0.83. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -1.55.

During the past 3 years, the average EPS without NRI Growth Rate was 27.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Trinity Biotech's highest 3-Year average EPS without NRI Growth Rate was 43.40% per year. The lowest was -57.80% per year. And the median was -8.00% per year.

Trinity Biotech  (NAS:TRIB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Trinity Biotech EPS (Basic) Related Terms

Trinity Biotech EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech EPS (Basic) Chart

Trinity Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 -6.00 -4.00 -2.00 -2.00

Trinity Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.46 -1.00 -1.00 -0.80 -1.20
TRIB
20GF Score
Trinity Biotech PLC TRIB
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Trinity Biotech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Trinity Biotech's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-37.376-0)/18.576
=-2.01

Trinity Biotech's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-22.612-0)/18.685
=-1.21

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-2.00 mean?
Trinity Biotech (TRIB) has a EPS (Basic) of $-2.00 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Trinity Biotech and its competitors.
Is Trinity Biotech's EPS (Basic) too high?
Trinity Biotech's current EPS (Basic) is $-2.00. Overall, Trinity Biotech has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's EPS (Basic) compare to PMI and NXL?
Trinity Biotech's EPS (Basic) of $-2.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Trinity Biotech and its competitors. Trinity Biotech's current EPS (Basic) is $-2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.33 — trading 54.8% below its estimated fair value. The current EPS (Basic) is $-2.00. Trinity Biotech's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current EPS (Basic) is $-2.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.33 is trading 54.8% below its estimated GF Value™ of $0.73. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • EPS (Basic): $-2.00
  • GF Value™: $0.73 vs. price of $0.33 (54.8% below fair value)
  • GF Score™: 20/100 with 7 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
20GF Score

Get the complete analysis for TRIB

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.73
GF Value